In addition, we previously demonstrated that p16 loss increases mTORC1 activity (12), and a recent study found that cancers with increased mTORC1, such as those with TSC2 deficiency, are highly sensitive to inhibitors of IMPDH (53). The gene discussed is CDKN2A; the disease is cancer.